Skip to content
Johnson & Johnson (J&J)
-
Johnson & Johnson expands oncology portfolio with USD3B acquisition of Halda Therapeutics
Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.